Cytomegalovirus (CMV) Infections Market Insights, Epidemiology and Market Forecast – 2027



Albany, NY -- (SBWire) -- 10/01/2018 --DelveInsight has announced the addition of the " Cytomegalovirus (CMV) Infections Market Insights, Epidemiology and Market Forecast – 2027" to their offering.

DelveInsight's "Cytomegalovirus (CMV) Infections – Market Insights, Epidemiology & Market Forecast-2027" Report provides an overview of the disease and market size of CMV for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and Cytomegalovirus (CMV) Infections forecasted epidemiology from 2018 to 2027 segmented by seven major markets.

Cytomegalovirus(CMV) is a ubiquitous virus that infects the majority of humans of all ages. CMV is a member of the herpes virus family, which includes the herpes simplex viruses and the viruses that cause chickenpox and mononucleosis. Human Cytomegalovirus (HCMV) is a species of the Cytomegalovirus genus of viruses, of the viral family Herpes viridae or herpes viruses, and is the most common of all Cytomegaloviruses. There are three main types of CMV infections: acquired, recurring, or congenital. Transmission of the virus occurs through exposure to body fluids including blood, urine, saliva, breast milk, tears, semen and vaginal fluids; may not be by casual contact. CMV can cause retinitis (blurred vision and blindness), painful swallowing (dysphagia), pneumonia, diarrhoea (colitis), and weakness or numbness in the legs. Seroprevalence increases gradually with age and is usually higher in females than in males.

According to DelveInsight, the total diagnosed incident population of Cytomegalovirus (CMV) Infections in the 7 major markets (7MM) commences from 102,435 cases in 2016 to growing number of cases in 2027 in the period of 2016-2027. DelveInsight also estimates higher diagnosed patients of CMV infections in the United States with 65,214 cases in 2016, followed by the EU5 and Japan. Among the European countries, France had the highest diagnosed incident cases of CMV infections followed by Germany in 2016. On the other hand, Italy had the lowest diagnosed incident population.

The market study carried out for the period of 2016-2027 shows that the market size of Cytomegalovirus Infections was about USD 840.64 million in 2016 in the 7MM.

Geography Covered
1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2018-2027

Cytomegalovirus Drug Companies
1. Shire
2. Bitoest AG
3. Atara Biotherapeutics
4. Novartis

And many others

Drugs covered

1. Valganciclovir
2. Ganciclovir
3. Cidofovir
4. Foscarnet

And many others

Report Scope

The report covers a descriptive overview of the Cytomegalovirus (CMV) Infections, explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Cytomegalovirus (CMV) Infections and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Cytomegalovirus (CMV) Infections are provided, along with an assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Cytomegalovirus (CMV) Infections market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cytomegalovirus (CMV) Infections market.

Media Relations Contact

Ankit Nigam

View this press release online at: